Associations of oxaliplatin dose, lean body mass, and sarcopenia with dose-limiting neuropathy in patients with colorectal cancer
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Nadira R Querido und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Electronic add…. Hauptthemen laut MEDLINE: Oxaliplatin, Sarcopenia, Colorectal Neoplasms, Peripheral Nervous System Diseases. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Dutch Cancer Society, World Cancer Research Fund Netherlands, Kankeronderzoekfonds Limburg.
Abstract (Originalsprache)
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of oxaliplatin, currently dosed by body surface area (BSA). BSA does not account for differences in lean body mass (LBM) that may influence toxicity. We assessed the independent and interactive effects of oxaliplatin dose, LBM, and sarcopenia on CIPN in colorectal cancer (CRC) patients. METHODS: Data were analyzed from CRC patients treated with adjuvant CAPOX in routine care. CIPN after each cycle was assessed from medical records using CTCAE v5.0; with grade ≥2 CIPN considered dose-limiting. The initial oxaliplatin dose was obtained from health records. LBM was estimated from diagnostic abdominal CT scans, and sarcopenia was defined using sex-specific skeletal muscle index cut-offs. Associations between initial oxaliplatin dose, LBM, and sarcopenia with time to first grade ≥2 CIPN were estimated using Cox-regression. Stratified analyses by LBM and sarcopenia were conducted to assess whether they modified the association between initial dose and CIPN. RESULTS: Among 106 patients, 36 (34%) developed grade ≥2 CIPN during the first four cycles. More women experienced grade ≥2 CIPN (40%) than men (30%). Initial oxaliplatin dose, LBM, and sarcopenia were not significantly associated with grade ≥2 CIPN. No significant interactions were found between initial dose and LBM or sarcopenia. Notably, women had higher oxaliplatin dose intensity than men when normalized to LBM (5.5 vs 4.7 mg/kg), reflecting a larger discrepancy between their LBM and BSA. CONCLUSION: Although no significant associations were observed, sex-differences in LBM- adjusted dose intensity may suggest a potential role for LBM as a parameter in oxaliplatin dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Electronic address: nadira.ribeiroquerido@maastrichtuniversity.nl.
- Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
- Department of Internal Medicine, Division of Medical Oncology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- Department of Surgery, GROW Research Institute for Oncology and Reproduction, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands; Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands.
- Department of Internal Medicine and Gastroenterology, Zuyderland Medical Centre Sittard-Geleen, Geleen, The Netherlands.
Förderung
- KWF Dutch Cancer Society
- World Cancer Research Fund Netherlands
- Kankeronderzoekfonds Limburg
Zitieren
APA
Querido, N. R., Bours, M. J. L., Valkenburg-van Iersel, L., Beijers, A. J. M., Breukink, S. O., Janssen-Heijnen, M. L. G., Keulen, E. T. P., Konsten, J. L. M., de Vos-Geelen, J., Weijenberg, M. P., & Simons, C. C. J. M. (2026). Associations of oxaliplatin dose, lean body mass, and sarcopenia with dose-limiting neuropathy in patients with colorectal cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101347
Vancouver
Querido NR, Bours MJL, Valkenburg-van Iersel L, Beijers AJM, Breukink SO, Janssen-Heijnen MLG, et al. Associations of oxaliplatin dose, lean body mass, and sarcopenia with dose-limiting neuropathy in patients with colorectal cancer. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101347
BibTeX
@article{Querido2026,
author = {Querido, Nadira R and Bours, Martijn J L and Valkenburg-van Iersel, Liselot and Beijers, Antoinetta J M and Breukink, Stephanie O and Janssen-Heijnen, Maryska L G and Keulen, Eric T P and Konsten, Joop L M and de Vos-Geelen, Judith and Weijenberg, Matty P and Simons, Colinda C J M},
title = {Associations of oxaliplatin dose, lean body mass, and sarcopenia with dose-limiting neuropathy in patients with colorectal cancer},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101347}
}
EUVIMED